Clinical outcomes according to age at diagnosis of HCL
| . | ≤40 y of age (n = 88) . | All patients (n = 209)6 . |
|---|---|---|
| Median age (range) | 36 y (20-40) | 50 y (28-79) |
| Response rate | 100% | 100% |
| Complete | 88% | 95% |
| Partial | 12% | 5% |
| Median response duration (mo) | 57 (range, 7-246 mo) | 98 (range, 8-172 mo) |
| Relapse rate | 58% | 37% |
| Median time to relapse (mo) | 54 (range, 7-246 mo) | 42 (range, 8-118 mo) |
| Observed-to-expected ratio of developing a second malignancy | 1.60 (95% CI, 0.80-2.89) | 2.03 (95% CI, 1.49-2.71) |
| . | ≤40 y of age (n = 88) . | All patients (n = 209)6 . |
|---|---|---|
| Median age (range) | 36 y (20-40) | 50 y (28-79) |
| Response rate | 100% | 100% |
| Complete | 88% | 95% |
| Partial | 12% | 5% |
| Median response duration (mo) | 57 (range, 7-246 mo) | 98 (range, 8-172 mo) |
| Relapse rate | 58% | 37% |
| Median time to relapse (mo) | 54 (range, 7-246 mo) | 42 (range, 8-118 mo) |
| Observed-to-expected ratio of developing a second malignancy | 1.60 (95% CI, 0.80-2.89) | 2.03 (95% CI, 1.49-2.71) |
CI, confidence interval.